
Drug-resistant gonorrhoea: a wake-up call that AMR is now a community-wide threat
A surge in drug-resistant gonorrhoea in Europe shows antimicrobial resistance is spreading through everyday contact and travel, not just hospitals, with LMICs bearing a heavy burden as treatment options dwindle. The situation underscores the need for stronger antibiotic stewardship, surveillance, and new drug development—ideally via not-for-profit models like zoliflodacin—to ensure access and sustainable use across all countries; otherwise common infections could become increasingly hard or impossible to treat.



